Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2022-09-28 Regulatory Filings
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(민군겸용 기술개발사업(형질전환돼지 기반 수혈가능 이종적혈구제제 기술개발) 국책과제 선정)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Optipharm) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing the selection for a government-funded research project. This type of disclosure is a standard regulatory requirement in the Korean market for material corporate events. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2022-09-28 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Optipharm' (주식회사 옵티팜) for the period covering January 1, 2022, to June 30, 2022. It contains detailed financial information, business descriptions, and management reports, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-12 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Optipharm' (주식회사 옵티팜) covering the period from January 1, 2022, to March 31, 2022. It contains detailed business descriptions, financial data, and management information. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (quarterly) is classified as an Interim / Quarterly Report (IR). Q1 2022
2022-05-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific director (Kim Hyun-il) of the company Optipharm. This type of filing is a standard regulatory requirement for insider trading or changes in ownership by company insiders, which corresponds to the 'Director's Dealing' category.
2022-04-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in shareholdings by company directors. This corresponds to the 'Director's Dealing' category.
2022-04-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report insider trading or changes in share ownership by company directors and major shareholders. Based on the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2022-04-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.